Revenue from operations rises by 44 per cent on a standalone basis
Kilitch Drugs recently announced its unaudited financial results for the quarter ended on March 31, 2025. The company reported a 178 per cent year-on-year (Y-o-Y) rise in consolidated profit after tax (PAT) for the Q4 FY25 to Rs 1,021.86 lakh from Rs 368.07 lakh for the corresponding period the previous year.
The company recorded its quarterly consolidated revenue from operations at Rs 6,122.58 lakh in Q4FY25, experiencing 37 per cent Y-o-Y excellence growth from Rs. 4,481.88 lakh in Q4FY24. The growth is achieved by continuous efforts to meet steady demand across globe and will continue further.
Consecutively, the company’s standalone PAT rose by 212 per cent, and revenue grew by 44 per cent to Rs 1,137.41 lakh and Rs 18,158.73 lakh recorded in Q4 FY25, respectively. For the year ending March 2025, In FY25, Kilitch reported an over 77 per cent YoY rise in standalone net profit to Rs 3,115.69 lakh, compared to Rs 1,757.38 lakh in FY24. The standalone revenue from operation for the period increased by 38 per cent to Rs 18,158.73 lakh from Rs 13,159.90 lakh in the previous year.
Mukund Mehta, MD, Kilitch Drugs said, “We witnessed significant growth in our performance for this year; revenue from operations grew by 44 per cent and PAT increased by 212 per cent on a standalone basis as compared to Q4FY2024. We remain focussed on driving sustainable growth and delivering strong returns for our stakeholders.”
